Tiziana Life Sciences Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated June 12, 2020, reports on an amendment to an existing At-The-Market (ATM) Sales Agreement entered into by Tiziana Life Sciences plc. The filing updates the termination date of the agreement originally disclosed on April 10, 2020.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the aggregate offering price of up to $20 million for American Depositary Shares (ADSs) under the ATM program.
Material Changes
On June 9, 2020, the Company and ThinkEquity amended the Offering Agreement to extend the termination date from June 11, 2020, to July 31, 2020. No other material changes to the offering structure or terms were disclosed in this filing.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies beyond the standard terms of the ATM agreement. The unusual item noted is the extension of the sales window to allow additional time for the potential sale of ADSs.
Key Facts for Investor Verification
- The ATM program allows for the sale of up to $20 million in ADSs.
- The termination date for the ATM agreement was extended to July 31, 2020.
- ThinkEquity, a division of Fordham Financial Management, Inc., serves as the sales agent.
- Each ADS represents five ordinary shares with a nominal value of £0.03.
- The filing does not disclose the actual amount of shares sold or proceeds raised to date.